Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

MLA

Allan, Jn, et al. Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukaemia in Patients with TP53 Aberrations: A Pooled Analysis from Four Clinical Trials. Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....bd98128c4bf54823a02e4323e5cd84b5&authtype=sso&custid=ns315887.

APA

Allan, J., Shanafelt, T., Wiestner, A., Moreno, C., O’Brien, S., Li, J., Krigsfeld, G., Dean, J., & Ahn, I. (2022). Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.

Chicago

Allan, Jn, T Shanafelt, A Wiestner, C Moreno, Sm O’Brien, Jl Li, G Krigsfeld, Jp Dean, and Ie Ahn. 2022. “Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukaemia in Patients with TP53 Aberrations: A Pooled Analysis from Four Clinical Trials,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....bd98128c4bf54823a02e4323e5cd84b5&authtype=sso&custid=ns315887.